Filtered By:
Source: bizjournals.com Health Care:Biotechnology headlines
Management: Mergers and Aquisitions
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
Ahead of Shire buyout, Takeda sells joint venture and reportedly plans $20B bond deal
Japanese pharmaceutical giant Takeda is boosting its finances ahead of its costly acquisition of Shire plc, selling its stake in a Chinese joint venture for $280 million and reportedly planning a record $20 billion bond deal.
Takeda announced Monday that it had sold its majority stake in a joint venture called Guangdong Techpool Bio-Pharma Co., which sells drugs for pancreatitis and stroke. The move is part of a broader effort by Takeda to ditch assets outside of its core focus areas, including…
Source: bizjournals.com Health Care:Biotechnology headlines - May 22, 2018 Category: Biotechnology Authors: Max Stendahl Source Type: news
Jefferson, Magee complete merger
Jefferson Health added its fourth new member since 2015 with the completion of its merger with Magee Rehabilitation Hospital.
The leaders of Jefferson and Magee said Tuesday the integration will enable two organizations, both nationally ranked, to provide “an even higher level of care” to patients regaining independence from spinal cord injury, stroke, brain injury, amputation, multiple sclerosis and/or orthopedic injuries.
Jefferson and Magee have had a clinical affiliation for several decades.…
Source: bizjournals.com Health Care:Biotechnology headlines - January 23, 2018 Category: Biotechnology Authors: John George Source Type: news
Boston Scientific's Watchman stroke prevention device approved after 4 years
Boston Scientific's Watchman device, an alternative to blood thinners for stroke prevention, has earned approval in the U.S. four years after the medical device giant bought the product in its $375 million acquisition of Atritech.
The Watchman Left Atrial Appendage Closure Device has been called one of "the two most meaningful pipeline products (along with the Synergy stent) expected to launch over the next few years" by Leerink Partners analyst Danielle Antalffy.
Mike Mahoney, the CEO of Marlborough,…
Source: bizjournals.com Health Care:Biotechnology headlines - March 15, 2015 Category: Biotechnology Authors: Don Seiffert Source Type: news
